Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e1401 (Published 27 March 2012) Cite this as: BMJ 2012;344:e1401
All rapid responses
The findings in table 3 are not unexpected. As reported previously by Brown et al.[1] and as stated in our manuscript,[2] we have also previously shown in the FUTURE I and II clinical trials that vaccination reduced the incidence of cervical intraepithelial neoplasia grade 3 or worse associated with 10 non-vaccine HPV types by 32.5% (6.0% to 51.9%), and the analyses in Table 3 suggest some of the subsequent disease that is prevented is due to protection against HPV types that are phylogenetically related to HPV6/11/16/18.
Also, as stated in our manuscript,[2] another study has shown the HPV6/11/16/18 vaccine generates an anamnestic response in women aged 15-26 who are seropositive pre-vaccination,[3, 4] and that the HPV6/11/16/18 vaccine prevents reinfection or reactivation of disease that is related to vaccine HPV types.[5]
The data presented in our manuscript also showed that only 2 women in the vaccine arm developed HPV6/11/16/18-related cervical disease post-surgery, compared with 9 in the placebo arm, corresponding to a vaccine efficacy of 79%. Six of the 9 women in the placebo arm who developed HPV6/11/16/18-related cervical disease post-surgery had a vaccine HPV type that was not detected in the original surgical specimen, suggesting the lesion that was diagnosed post-surgery was from a new infection and not due to residual disease. Four of the 6 women in the placebo group that developed HPV6/11/16/18-related cervical intraepithelial neoplasia post-surgery with an HPV type not in the original surgical specimen also reported at least one new partner during the interval between the first surgical surgery and the subsequent disease diagnosis.
For these reasons, the authors conclude the observed efficacy is related to vaccination. Although the exact underlying mechanism is not fully known, these observed reductions are felt to be clinically significant.
References
1. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naive women aged 16-26. J Infect Dis 2009;199(7):926-935.
2. Joura EA, Garland SM, Paavonen J et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.
3. Villa LL, Ault K, Giuliano AR et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006;24(27-28):5571-5583.
4. Olsson S-E, Villa LL, Costa R et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 2007;25(26):4931-4939.
5. Olsson S-E, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines 2009;5(10):696-704.
Competing interests: EAJ has received advisory board fees from Merck, and funding through his institution to conduct epidemiological HPV studies for GlaxoSmithKline. In addition he has received lecture fees from Merck, Sanofi Pasteur MSD and GlaxoSmithKline. HLS and RMH and are employees of Merck and potentially own stock and/or stock options in the company.
Vaccines composed of virus-like particles (VLPs) made from the L1 major capsid protein of specific HPV types induce a polyclonal antibody response. In the clinical trials of the quadrivalent vaccine, antibodies to the HPV L1 VLPs were measured by a competitive Luminex immunoassay (cLIA).[1,2] This type-specific assay measures antibody binding to a single neutralizing epitope for each HPV-type VLP, that is, it measures a subset of the total immune response to quadrivalent HPV VLP vaccination.[1, 2] Other immunoassays have also been developed that measure total IgG antibody binding to HPV VLPs.[3]
A recent study illustrated potential important differences in serologic assays utilized in the clinical trials of the two currently available HPV VLP vaccines (quadrivalent and bivalent).[4] The conclusion of Brown and coworkers was "Differences in seropositivity status are attributed to the measurement parameters and sensitivity of the individual immunoassays and do not indicate reduced anti-HPV18 protective antibodies." In the study by Brown and coworkers, the same sera from women vaccinated with the quadrivalent HPV vaccine were tested in both the total IgG LIA and the cLIA assays. Seropositivity for HPV18 remained high (96.7%) in the total IgG LIA at 48 months, but was 64.8% in the cLIA. This study illustrates potential important differences in serologic assays utilized in the clinical trials of the two currently available HPV VLP vaccines.
Recently, the CDC published a review of the systems in place or being established for post-licensure monitoring of HPV vaccines in the US.[5] A summary of the post-licensure safety and effectiveness studies being conducted in collaboration with the vaccine’s manufacturers and marketers (Merck and Co., Inc., Sanofi Pasteur MSD) as well as other known independent initiatives in Europe, Canada, and Australia have also been published.[6]
The understanding of the antibody responses to these vaccines is not complete, and there is no established immune correlate of protection or antibody threshold that correlates with protection against HPV infection or disease.[4] In addition, there is no standardized commercially available assay to measure antibody levels. The surveillance efforts for the quadrivalent vaccine represent one of the most comprehensive vaccine surveillance programs to date and will ultimately assess its long-term safety and effectiveness in vaccinated populations.
References
1. Opalka D, Lachman CE, MacMullen SA et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003;10(1):108-115.
2. Dias D, Van Doren J, Schlottmann S et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005;12(8):959-969.
3. Opalka D, Matys K, Bojczuk P et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010;17(5):818-827.
4. Brown DR, Garland SM, Ferris DG et al. The humoral response to Gardasil(R) over four years as defined by Total IgG and competitive Luminex immunoassay. Hum Vaccin 2011;7(2):epub ahead of print.
5. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010;28(30):4731-4737.
6. Bonanni P, Cohet C, Kjaer SK et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD(R). Vaccine 2010;28(30):4719-4730.
Competing interests: EAJ has received advisory board fees from Merck, and funding through his institution to conduct epidemiological HPV studies for GlaxoSmithKline. In addition he has received lecture fees from Merck, Sanofi Pasteur MSD and GlaxoSmithKline. HLS and RMH and are employees of Merck and potentially own stock and/or stock options in the company.
Human papillomavirus (HPV) quadrivalent vaccine cannot prevent progression of HPV infection to cervical lesion in women with ongoing HPV infection at the time of vaccination. The retrospective pooled analysis has demonstrated that HPV vaccine can significantly decrease the incidence of vaccine HPV 16/18 related-, non vaccine HPV 31 related- any subsequent cervical lesion in patients after cervical surgery. Vaccine was also associated with non-significant decrease of cervical intraepithelial neoplasia grade 1 or worse for seven other high-risk type of HPV, recurrent vulvar or vaginal low grade disease (genital warts, vulvar intraepithelial neoplasia grade I, or vaginal intraepithelial neoplasia grade I).
These conclusions are based on the two clinical trials of four years follow-up. However, authors have mentioned that prophylactic HPV vaccine can be efficacious for atleast 10 years quoting Rowhani-Rahbar A et al in their reference. Rowhani-Rahbar A et al have followed their monovalent HPV 16 vaccine recipient for period ranging from 7.2 to 9.5 years[1]. Bivalent HPV (type 16/18) and quadrivalent HPV (type 6/11/16/18) vaccine has shown their clinical efficacy against infection and cervical lesion for maximum period of 8.4 years and 5 years respectively[2,3]. Although the immune response of quadrivalent vaccine against HPV type 16 is maintained at five years, it wanes considerably against HPV type 18. Efficacy of quadrivalent vaccine is maintained against HPV 18 associated clinical endpoints despite the waning antibody level. There is no correlation between antibody level against HPV and the protection it offers against subsequent infection, cervical and other genital lesions[3,4]. Long-term surveillance of vaccinated subjects should include not only clinical follow-up of subjects to ascertain the efficacy of HPV vaccines but also correlation of titres of vaccine-induced antibody level with clinical efficacy.
References
1. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. Vaccine 2009;27:5612-9.
2. Roteli-Martins CM, Naud P, Borba P, Teixeira J, De Carvalho N, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: follow-up to 8.4 years. Abstract presented at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Nice, France,May 4–8, 2010.
3. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins A, Schiund A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection
with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
4. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26:6844-51.
Competing interests: No competing interests
The authors describe their significant finding as "The incidence of any subsequent HPV related disease was 6.6 and 12.2 in vaccine and placebo recipients respectively (46.2% reduction (95% confidence interval 22.5% to 63.2%) with vaccination)" This is further detailed in table 2.
Furthermore the authors describe an unexpected finding in table 3: "Impact of quadrivalent HPV vaccine on incidence of subsequent cervical intraepithelial neoplasia grade I or worse* associated with 10 tested non-vaccine HPV types among women who had undergone cervical surgery". The effect is similar, a 42.5% reduction.
In summary, the authors found a similar reduction in subsequent diseases of all HPV types (46.2%) and non-vaccine HPV types (42.5%). This leads to the conclusion that the reduction in subsequent disease was unrelated to the vaccination. The only other possibility would imply that the vaccine was active even on virus types not contained in the vaccine.
Competing interests: No competing interests
Re: Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
Dear Editors,
It would be interesting to follow all these vaccinated women to examine breast cancer incidence.
Since HPV infections are associated with breast cancers[references below], effective vaccinations might prove protective!
References
http://www.ncbi.nlm.nih.gov/pubmed/19851859
http://www.ncbi.nlm.nih.gov/pubmed/19773762
http://www.ncbi.nlm.nih.gov/pubmed/19724278
http://www.ncbi.nlm.nih.gov/pubmed/18936692
http://www.ncbi.nlm.nih.gov/pubmed/18427947
http://www.ncbi.nlm.nih.gov/pubmed/16865407
http://www.ncbi.nlm.nih.gov/pubmed/23183846
http://www.ncbi.nlm.nih.gov/pubmed/23011481
http://www.ncbi.nlm.nih.gov/pubmed/22566779
http://www.ncbi.nlm.nih.gov/pubmed/22214962
http://www.ncbi.nlm.nih.gov/pubmed/22012724
http://www.ncbi.nlm.nih.gov/pubmed/18648363
http://www.ncbi.nlm.nih.gov/pubmed/18413729
http://www.ncbi.nlm.nih.gov/pubmed/17310842
http://www.ncbi.nlm.nih.gov/pubmed/16780823
http://www.ncbi.nlm.nih.gov/pubmed/16222323
http://www.ncbi.nlm.nih.gov/pubmed/15642157
http://www.ncbi.nlm.nih.gov/pubmed/15494272
Competing interests: No competing interests